Anti-neutrophilic inflammatory activity of ASP3258, a novel phosphodiesterase type 4 inhibitor

International Immunopharmacology

Volumn 12, Issue 1, 2012, Pages 59-63

  Kubo, Satoshi ^a   Kobayashi, Miki ^a   Iwata, Masahiro ^a   Miyata, Keiji ^a   Takahashi, Koichiro ^a   Shimizu, Yasuaki ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

ASP3258; COPD; Neutrophil; Phosphodiesterase 4; Pulmonary inflammation

Indexed keywords

ANTIINFLAMMATORY AGENT; ASP 3258; CILOMILAST; PHOSPHODIESTERASE IV INHIBITOR; PREDNISOLONE; ROFLUMILAST; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTINEUTROPHILIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUNG LAVAGE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NORMAL HUMAN; PNEUMONIA; PRIORITY JOURNAL; RAT;

ADULT; AMINOPYRIDINES; ANIMALS; ANTI-INFLAMMATORY AGENTS; BENZAMIDES; BRONCHOALVEOLAR LAVAGE FLUID; CELLS, CULTURED; CHEMOKINE CXCL1; CYCLOHEXANECARBOXYLIC ACIDS; CYCLOPROPANES; GLUCOCORTICOIDS; HUMANS; LIPOPOLYSACCHARIDES; MALE; NAPHTHYRIDINES; NEUTROPHILS; NITRILES; PHOSPHODIESTERASE 4 INHIBITORS; PNEUMONIA; PREDNISOLONE; RATS; RATS, WISTAR; SUPEROXIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84856082197     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2011.10.011     Document Type: Article

References (28)

1. J.K. Quint, and J.A. Wedzicha The neutrophil in chronic obstructive pulmonary disease J Allergy Clin Immunol 119 2007 1065 1071 (Pubitemid 46654162)
2. G. Balamayooran, S. Batra, M.B. Fessler, K.I. Happel, and S. Jeyaseelan Mechanisms of neutrophil accumulation in the lungs against bacteria Am J Respir Cell Mol Biol 43 2010 5 16
3. C. Summers, S.M. Rankin, A.M. Condliffe, N. Singh, A.M. Peters, and E.R. Chilvers Neutrophil kinetics in health and disease Trends Immunol 31 2010 318 324
4. R.A. Pauwels, A.S. Buist, P.M. Calverley, C.R. Jenkins, and S.S. Hurd Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary Am J Respir Crit Care Med 163 2001 1256 1276 (Pubitemid 32378468)
5. P.J. Barnes, S.D. Shapiro, and R.A. Pauwels Chronic obstructive pulmonary disease: molecular and cellular mechanisms Eur Respir J 22 2003 672 688 (Pubitemid 37258549)
6. M.G. Belvisi Regulation of inflammatory cell function by corticosteroids Proc Am Thorac Soc 1 2004 207 214
7. J.E. Souness, D. Aldous, and C. Sargent Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors Immunopharmacology 47 2000 127 162 (Pubitemid 30394536)
8. M.A. Giembycz Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here? Drugs 59 2000 193 212 (Pubitemid 30168507)
9. P.M. Calverley, F. Sanchez-Toril, A. McIvor, P. Teichmann, D. Bredenbroeker, and L.M. Fabbri Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease Am J Respir Crit Care Med 176 2007 154 161 (Pubitemid 47057851)
10. P.M. Calverley, K.F. Rabe, U.M. Goehring, S. Kristiansen, L.M. Fabbri, and F.J. Martinez Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials Lancet 374 2009 685 694
11. L.M. Fabbri, P.M. Calverley, J.L. Izquierdo-Alonso, D.S. Bundschuh, M. Brose, and F.J. Martinez Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials Lancet 374 2009 695 703
12. S.I. Rennard, N. Schachter, M. Strek, K. Rickard, and O. Amit Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4 Chest 129 2006 56 66 (Pubitemid 43265243)
13. L.M. Fabbri, B. Beghe, U. Yasothan, and P. Kirkpatrick Roflumilast Nat Rev Drug Discov 9 2010 761 762
14. M. Kobayashi, S. Kubo, M. Iwata, Y. Ohtsu, K. Takahashi, and Y. Shimizu ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity Int Immunopharmacol 11 2011 732 739
15. B. Haddad el, K. McCluskie, M.A. Birrell, D. Dabrowski, M. Pecoraro, and S. Underwood Differential effects of ebselen on neutrophil recruitment, chemokine, and inflammatory mediator expression in a rat model of lipopolysaccharide-induced pulmonary inflammation J Immunol 169 2002 974 982 (Pubitemid 34753456)
16. D.C. Underwood, R.R. Osborn, S. Bochnowicz, E.F. Webb, D.J. Rieman, and J.C. Lee SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung Am J Physiol Lung Cell Mol Physiol 279 2000 L895 L902
17. Y.C. Xie, X.W. Dong, X.M. Wu, X.F. Yan, and Q.M. Xie Inhibitory effects of flavonoids extracted from licorice on lipopolysaccharide-induced acute pulmonary inflammation in mice Int Immunopharmacol 9 2009 194 200
18. J.D. Crapo, J.M. McCord, and I. Fridovich Preparation and assay of superoxide dismutases Methods Enzymol 53 1978 382 393
19. P.J. Barnes The cytokine network in asthma and chronic obstructive pulmonary disease J Clin Invest 118 2008 3546 3556
20. T. Himi, I. Yoshioka, and A. Kataura Production and gene expression of IL-8-like cytokine GRO/CINC-1 in rat nasal mucosa Acta Otolaryngol 117 1997 123 127 (Pubitemid 27077018)
21. S. Rajendrasozhan, J.W. Hwang, H. Yao, N. Kishore, and I. Rahman Anti-inflammatory effect of a selective IkappaB kinase-beta inhibitor in rat lung in response to LPS and cigarette smoke Pulm Pharmacol Ther 23 2010 172 181
22. M.F. Tosi, J.M. Stark, C.W. Smith, A. Hamedani, D.C. Gruenert, and M.D. Infeld Induction of ICAM-1 expression on human airway epithelial cells by inflammatory cytokines: effects on neutrophil-epithelial cell adhesion Am J Respir Cell Mol Biol 7 1992 214 221
23. M.S. Mulligan, A.A. Vaporciyan, M. Miyasaka, T. Tamatani, and P.A. Ward Tumor necrosis factor alpha regulates in vivo intrapulmonary expression of ICAM-1 Am J Pathol 142 1993 1739 1749 (Pubitemid 24057068)
24. W.J. Ming, L. Bersani, and A. Mantovani Tumor necrosis factor is chemotactic for monocytes and polymorphonuclear leukocytes J Immunol 138 1987 1469 1474 (Pubitemid 17029442)
25. S.J. Skerrett, T.R. Martin, E.Y. Chi, J.J. Peschon, K.M. Mohler, and C.B. Wilson Role of the type 1 TNF receptor in lung inflammation after inhalation of endotoxin or Pseudomonas aeruginosa Am J Physiol 276 1999 L715 L727
26. S.D. Shapiro Animal models for COPD Chest 117 2000 223S 227S (Pubitemid 30326959)
27. C.S. Stevenson, and M.G. Belvisi Preclinical animal models of asthma and chronic obstructive pulmonary disease Expert Rev Respir Med 2 2008 631 643
28. S. Kubo, M. Kobayashi, M. Iwata, K. Takahashi, K. Miyata, and Y. Shimizu Disease-modifying effect of ASP3258, a novel phosphodiesterase type 4 inhibitor, on subchronic cigarette smoke exposure-induced lung injury in guinea pigs Eur J Pharmacol 659 2011 79 84